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Abstract
Background: Two major cities in West Africa, Accra, the capital of Ghana, and Lagos, the largest city of Nigeria, have 
significant problems with substandard pharmaceuticals. Both have actively combated the problem in recent years, 
particularly by screening products on the market using the Global Pharma Health Fund e.V. Minilab® protocol. Random 
sampling of medicines from the two cities at least twice over the past 30 months allows a tentative assessment of 
whether improvements in drug quality have occurred. Since intelligence provided by investigators indicates that some 
counterfeit producers may be adapting products to pass Minilab tests, the results are compared with those from a 
Raman spectrometer and discrepancies are discussed.
Methods: Between mid-2007 and early-2010, samples of anti-malarial drugs were bought covertly from pharmacies in 
Lagos on three different occasions (October 2007, December 2008, February 2010), and from pharmacies in Accra on 
two different occasions (October 2007, February 2010). All samples were tested using the Minilab® protocol, which 
includes disintegration and active ingredient assays as well as visual inspection, and most samples were also tested by 
Raman spectrometry.
Results: In Lagos, the failure rate in the 2010 sampling fell to 29% of the 2007 finding using the Minilab® protocol, 53% 
using Raman spectrometry, and 46% using visual inspection. In Accra, the failure rate in the 2010 sampling fell to 54% 
of the 2007 finding using the Minilab® protocol, 72% using Raman spectrometry, and 90% using visual inspection.
Conclusions: The evidence presented shows that drug quality is probably improving in both cities, especially Lagos, 
since major reductions of failure rates over time occur with all means of assessment. Many more samples failed when 
examined by Raman spectrometry than by Minilab® protocol. The discrepancy is most likely caused by the two 
techniques measuring different aspects of the medication and hence the discrepancy may be the natural variation in 
these techniques. But other explanations are possible and are discussed.
Background
The dangers of substandard drugs
Substandard drugs can be lethal; diseases like malaria kill
rapidly, and without effective drugs, death for a small per-
centage can come quickly. In addition to this problem, the
Plasmodium parasite which causes malaria, adapts over
time, becoming resistant to previously effective drugs.
This adaptation is accelerated if the treatments are sub-
strength - either low active ingredient, or low availability
of active ingredient due to poor formulation or product
degradation. It is crucial, therefore, that patients com-
plete the treatment course and that their drugs are prop-
erly formulated. Sadly, in some areas where malaria is
highly prevalent, treatments such as chloroquine, a cheap
and safe drug, now fail to cure because parasites have
developed resistance to it. Fake and substandard drugs
that are under-dosed promote resistance. Combating
such drugs is therefore important to ensure the continued
survival of drugs to fight malaria.
Nigeria and Ghana combat their fake drug problem
Since 2002, when nearly 41% of the drugs in the Nigerian
market were estimated to be fake, Nigeria's National
Agency for Food and Drug Administration and Control
(NAFDAC) has made significant efforts in combating
fake drugs [1,2]. NAFDAC has improved screening of
drugs in the field; it has undertaken forensic analysis of
low quality drugs and pursued those selling and market-
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ing them. Screening has improved with the deployment
of several small portable laboratories, known as Global
Pharma Health Fund e.V. Minilabs®  for rapid product
screening where formal laboratory facilities are sparse.
NAFDAC is also conducting a survey and audit of all
drugs on sale in order to build a pharmaceutical database.
From 2002, drug failures fell to roughly 16% in 2006 and
are now down to about 10%, according to the director-
general of NAFDAC, Dr. Paul Orhii (personal communi-
cation, February 25, 2010). Dr. Orhii is pushing further by
being the first anti-counterfeit department anywhere in
the world to deploy six hand-held laser (Raman) spec-
trometers, which can provide immediate authentication
of drugs. According to NAFDAC's Elizabeth Awagu, this
deployment is helping to close down more of those loca-
tions still selling fake products.
As a participating country in the President's Malaria
Initiative, Ghana has been assisted by the United States
Pharmacopeia (USP) and others in improving diagnostics
and laboratory facilities, including the deployment of
Minilabs similar to NAFDAC's actions in Nigeria. In July
2009, one of the five sentinel sites set up under the guid-
ance of USP, in association with Ghana's Food and Drugs
Board Quality Control Laboratory, was rewarded when a
local citizen brought in suspect artemether-lumefantrine
(Coartem®) - a leading brand of the newest artemisinin-
based combination therapy (ACT), which was found to
contain no active ingredient. Tens of thousands of treat-
ments of the fake were seized.
Methods
Sampling methods deployed in the drug collections were
developed in line with similar studies [3-5]. Anti-malarial
drugs were obtained by local nationals from randomly
selected private pharmacies in Lagos and Accra. Study
agents posed as customers and were instructed to stay
within a single neighbourhood and to select pharmacies
at first sight on a random walk, and were blind as to the
purpose for which they were collecting samples. They
purchased a sample lot of anti-malarial tablet formula-
tions, namely: sulphadoxine-pyrimethamine (SP), amodi-
aquine, mefloquine, artemisinin monotherapies and
ACT. Agents were instructed not to purchase chloro-
quine since it is no longer an effectual treatment in nearly
every country. All drugs in all pharmacies were available
without a prescription. Treatment packs included drugs
sold in the manufacturer's original packaging as well as
those distributed loose, often in paper bags. Once pur-
chased, all drugs were stored at ambient temperature,
with low humidity and no sunlight, until testing.
All samples and packaging were visually inspected for
obvious flaws in line with the protocol established by the
Global Pharma Health Fund e.V. Minilab®. The Minilab
was then used to run semi-quantitative thin-layer chro-
matography (TLC) and disintegration tests on each sam-
ple, within 60 days of collection, to determine the
presence and relative concentration of active ingredients.
Each test was run in duplicate, with the generous
assumption that the result more consistent with the refer-
ence was recorded. The Minilab protocols award prod-
ucts a "pass" if they have 80% or more of the labeled active
ingredient(s) (note there is no upper-bound limit). For
fixed-dose combinations and SP, a "pass" was awarded
only if both active ingredients met this standard. Quality
control of the Minilab was performed daily prior to drug
testing and consisted of performing TLC on Minilab-ref-
erence samples for the drug classes being analysed. In
addition, Minilab reagents were quality control tested
using reference samples when a new lot was introduced.
Samples were also tested using a portable Raman spec-
trometer (TruScan; Ahura Scientific, Inc., Wilmington,
MA). Spectrometers "fingerprint" materials without
using external substances. Unlike the Minilab assays
which focus on specific attributes of the medicines, the
spectra generated by the spectrometer reflect all contents
of the sample: active pharmaceutical ingredients, excipi-
ents, fillers, dyes, and coatings. The spectra will change
when any of these contents is changed or is inherently
different due to different manufacturers producing drugs
with different concentrations of excipients, and perhaps
entirely different excipients. Furthermore, temperature
degradation or moisture degradation of a sample will
affect the spectra, which is critical when assessing the
viability of compounds, such as artemisinin, whose effec-
tiveness is lowered by moisture. Methods were estab-
lished for the Raman spectrometer for each brand
studied, and testing was carried out in the same location
as the Minilab analysis. Of note, 39 samples could not be
properly assessed because methods could not be estab-
lished for those brands. For other brands, sample sizes
were small, and while spectral methods were established
for each brand, it is unknown if any reliability problems
from such sampling occurred, potentially biasing results.
Since the spectrometer is set to western compendial stan-
dards, methods should be assessed from a sizeable num-
ber of samples to avoid false negatives, which can be
found with natural product variability. Unfortunately this
was not possible with the majority of samples. Further-
more, unlike the Minilab assays, a failure by spectrometry
may indicate an intellectual property violation of a brand,
rather than a product which is a risk to public health.
Sample collections
Between mid-2007 and early-2010, study agents con-
ducted three samplings of pharmacies in Lagos (October
2007, December 2008, February 2010), and two samplings
of pharmacies in Accra during the same period (October
2007, February 2010). A total of 339 samples were col-Bate and Hess Malaria Journal 2010, 9:157
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lected and tested using the Minilab, of which 300 samples
were also tested with the same spectrometer (TruScan)
deployed by the Nigerian Government. In all, 15 different
pharmacies were sampled from the same area in Lagos;
over the three collections, eight were sampled more than
once due to the random selection protocol. Thirteen
pharmacies were sampled in Accra, eight of which were
sampled during both collections. It should be noted that
sample sizes are not large; indeed, the 2007 sampling in
Lagos included only 22 samples from only seven pharma-
cies.
Study agents were instructed to buy a variety of older
anti-malarial therapies. These include therapies newer
than chloroquine (not sought in this study but still avail-
able and a popular choice because of its low price and
familiarity); but which have been on sale for most of the
past thirty years - such as amodiaquine, mefloquine and
SP. Study agents also bought artemisinin monotherapies
where available. The World Health Organization (WHO)
strongly recommends that artemisinin be combined with
some other drug, which acts against malaria in a different
way, as a multi-pronged attack will reduce the risk of the
parasite developing resistance. It is disquieting that the
single formulation, which the WHO has for over three
years asked manufacturers not to produce or traders to
sell, was still widely available [6].
At the time of the 2007 sampling, the only ACT on sale
and testable using the Minilab was artemether-lumefan-
trine (AL); although Minilab testing of other forms of
ACT became available after 2007, these were not sampled
because of the testing constraint during the first collec-
tion. ACT is the first-line therapy recommended in every
African nation (bar two small nations where chloroquine
is still effective).
Results
Tables 1, 2 and 3 summarize the findings of the drug test-
ing results by drug type. Table 4 presents the failure rates
recorded by visual inspection, Minilab tests, and Raman
spectrometry tests for those drugs testable by spectrome-
try (300 of the original 339 samples - 39 samples of cer-
tain brands could not be assessed using the Raman
spectrometer because original products were not avail-
able by manufacturers). At first glance, the reduction in
failure rates identified by the Minilab in Accra and Lagos
appears to be good news: the obvious implication, if the
data reflect a wider phenomenon, is that anti-malarial
drug quality is improving in these cities. The overall fail-
ure rate for Minilab tests (TLC assay and/or disintegra-
tion) drops significantly from the 2007 sampling to the
2010 sampling in Lagos (35% or 7/20 to 10.3% or 9/87),
and in Accra (35.3% or 12/34 to 19.1% or 9/47). Packages
were visually screened for apparent trademark violations
or other obvious labeling infractions, which might imply
the product was counterfeit, or where the packaging was
so poor that the product was obviously degraded. Prod-
ucts were treated as suspicious if, for example, the manu-
facturing dates were after the product expiry dates, there
were incorrect spellings of product name or details of
production, or there were odd fonts or font sizes different
from innovator brands and branded generic originals.
There was a slight improvement in the visual inspection
failure rates from the 2007 sampling to the 2010 sam-
pling: from 15% (3/20) to 6.9% (6/87) in Lagos and 11.8%
(4/34) to 10.6% (5/47) in Accra.
This trend is continued with the drugs that failed
Raman spectrometer testing, although the spectrometer
fails a higher number of samples than visual inspection or
the Minilab assays. A similar finding was made in the
comparison of Minilab failure rates, which were far lower
than with the more sophisticated laboratory compendia
assessments, in the study of the Quality of Antimalarials
in sub-Saharan Africa (QAMSA). This is the product of
the Promoting the Quality of Medicines (PQM) partner-
ship funded by USAID and implemented by USP. The
first results, from Madagascar, Uganda and Senegal, are
part of a larger, ten-country study (QAMSA) imple-
mented by WHO in collaboration with USP.
Table 4 provides an interesting assessment of the
improvement in drug quality. For Lagos, samples failing
Minilab tests in the 2010 sampling fell to 29% (10.3/35
*100) of the 2007 sampling; those failing visual inspection
fell to 46% (6.9/15 *100) of the 2007 sampling, and those
failing spectrometry fell to 53% (18.4/35 *100). For Accra,
the respective figures are 54% (19.1/35.3 *100), 90% (10.6/
11.8 *100) and 72% (29.8/41.2 *100). From the 2008 sam-
pling to the 2010 sampling in Lagos, the fall is to 64%
(10.3/16.1 *100) for Minilab and 74% (18.4/25 *100) for
spectrometry.
Discussion
Since all chosen drug quality assessment methods show a
reduction in failure rates, it is reasonable to conclude that
the quality of anti-malarial drugs in the two cities has
probably improved between October 2007 and February
2010. The data are not sufficient to draw any firm conclu-
sions about differences between spectrometry and Mini-
lab results, particularly because the smallest differences
occur with the largest samples. Assuming the data reflect
real changes in the cities' drug markets, what might they
mean?
It has been known for at least five years that the Nige-
rian authorities, NAFDAC, and more recently, the Gha-
naian authorities, have been undertaking serious anti-
counterfeiting efforts. It is therefore quite likely that at
least some counterfeiters and those wilfully supplying
substandard products, which involve no labeling infrac-
tions, have left the market in search of less well-regulatedBate and Hess Malaria Journal 2010, 9:157
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locations. A more speculative possibility is that some of
these actors may have adapted in order to bypass or over-
come such efforts. This speculation has some weak sup-
port.
Ignoring visual inspection failures, which are a predic-
tor of quality and a useful guide for inspectors but are not
a quality assessment, there is a potentially important rela-
tive disparity between spectrometry testing and Minilab
testing results. Assuming an overall improvement in drug
quality, one would expect the failure rate to fall by
roughly the same relative amount in both methods of
assessment. Yet, for the same drugs there is a notably
lesser quality improvement shown by spectrometry test-
ing than the Minilab from the 2010 testing as compared
with the 2007 testing. The discrepancy is 24% for Lagos
(53% spectrometry, 29% Minilab) and 18% for Accra (72%
spectrometry, 54% Minilab). For the 2008 testing to the
2010 testing in Lagos the difference is only 10% (74%
spectrometry, 64% Minilab), and this may be the most
significant result because the 2008 sampling in Nigeria
was the largest by volume.
Anecdotal evidence from other markets suggests that
counterfeiters have learned to include small amounts of
active pharmaceutical ingredient (API) to pass basic anal-
ysis, such as colour dye tests, which tests only for the
presence of API, not the quantity. The Minilab resolves
this problem since its assay assesses semi-quantitatively
the concentration of API. However, from conversations
with investigators in India and China (probably the two
nations producing the most fake and substandard prod-
ucts), more counterfeiters are adding roughly the right
amount of API. This does increase the cost of production
and if API is hard to get, such as in the case of artemisi-
nin, this may increase the likelihood of exposure and
hence capture. Nevertheless, according to investigators,
such as Indian specialist, Suresh Sati, buying more API is
still a relatively low cost part of the operation (packaging
costs and infiltrating legitimate supply chains is where
investigators claim most of the money is spent).
After all, with greater API there is still no guarantee
that producers will formulate drugs properly, since it
requires real production skill to make a bioequivalent
product, but such counterfeit products might possibly
fool the Minilab API assay. Given the scarcity of national
laboratories to inspect products, which may be border-
line Minilab API assay failures, such a response by coun-
terfeiters may mean they escape detection - even in
better-protected locations like Nigeria. It may be that the
newer, but still substandard products have changed,
partly in response to better detection, possibly worsening
the problem of drug resistance. Such drugs may have pos-
itive impact on the patients' condition, but are more likely
not to cure, and are more likely to promote resistance,
and thus pose a much more insidious risk.
Of course, a happier and perhaps more likely interpre-
t a t i o n  i s  t h a t  w o r k  be i n g  d o n e  b y  t h e  g o v e r n m e n t s  o f
Ghana and Nigeria, the legitimate pharmaceutical supply
chain and others, such as USP, is showing success, and the
Table 1: Drug samples failing Minilab tests (API assay and disintegration)a
Sampling Older 
monotherapiesb
Artemisinin 
monotherapies
ACTsc Total Failures
Lagos 2007 3/8 3/7 1/7 7/22
Lagos 2008 8/59 12/65 1/5 21/129
Lagos 2010 5/30 6/47 1/17 12/94
Lagos Total 16/97 21/119 3/29 40/245
Accra 2007 5/13 5/16 3/8 13/37
Accra 2010 5/23 5/24 1/10 11/57
Accra Total 10/36 10/40 4/18 24/94
TOTAL 26/133 31/159 7/47 64/339
a. Numbers are total that failed testing/total samples tested
b. Includes amodiaquine, mefloquine or sulphadoxine-pyrimethamine
c. Artemisinin-based combination therapiesBate and Hess Malaria Journal 2010, 9:157
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Table 2: Drug samples failing visual inspection testsa
Sampling Older 
monotherapiesb
Artemisinin 
monotherapies
ACTsc Total Failures
Lagos 2007 1/8 1/7 1/7 3/22
Lagos 2008 3/59 9/65 0/5 12/129
Lagos 2010 4/30 3/47 0/17 7/94
Lagos Total 8/97 13/119 1/29 22/245
Accra 2007 1/13 2/16 1/8 4/37
Accra 2010 2/23 4/24 0/10 6/57
Accra Total 3/36 6/40 1/18 10/94
TOTAL 11/133 19/159 2/47 32/339
a. Numbers are total that failed testing/total samples tested
b. Includes amodiaquine, mefloquine or sulphadoxine-pyrimethamine
c. Artemisinin-based combination therapies
Table 3: Drug samples failing Raman spectrometry testsa
Sampling Older 
monotherapiesb
Artemisinin 
monotherapies
ACTc Total Failuresd
Lagos 2007 3/6 3/7 1/7 7/20
Lagos 2008 10/49 17/58 1/5 28/112
Lagos 2010 8/28 7/44 1/15 16/87
Lagos Total 21/83 27/109 3/27 51/219
Accra 2007 5/11 6/15 3/8 14/34
Accra 2010 5/16 8/23 1/8 14/47
Accra Total 10/27 14/38 4/16 28/81
TOTAL 31/110 41/147 7/43 79/300
a. Numbers are total that failed testing/total samples tested
b. Includes amodiaquine, mefloquine or sulphadoxine-pyrimethamine
c. Artemisinin-based combination therapy
d. Only 88% of total samples were tested by spectrometry (300 out of 339), since the TruScan spectrometer requires a known good quality version 
for comparison and for 39 samples this could not be established.Bate and Hess Malaria Journal 2010, 9:157
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discrepancy between the results of the spectrometry and
Minilab tests is a statistical outlier. Or it is perhaps
explained by some unreliable methods established for the
spectrometer given the limited reference samples, which
could increase the chance of false negatives.
Conclusions
The data presented in this paper show a marked improve-
ment in anti-malarial drug quality in Accra and especially
Lagos over the past three years, as indicated by all of the
quality tests undertaken. It is to be hoped that this
reflects a general improvement in quality in these two cit-
ies rather than some statistical anomaly.
Many more samples failed when examined by Raman
spectrometry than by Minilab® protocol. The discrepancy
is most likely caused by the two techniques measuring
different aspects of the medication and hence the dis-
crepancy may be the natural variation in these tech-
niques. But other explanations are possible. Since one
possible explanation, which has some anecdotal support,
is that counterfeiters are adapting their actions to fool the
more basic Minilab API assay, while not making a quality
product, it is recommended that all users of the Minilab
API assay periodically test some of their samples, which
pass the API assay, with other techniques.
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